Results for tag: "Dystrophin"

The Dystrophin market is a subset of the Musculoskeletal Disorders Drugs market, which focuses on treatments for diseases that affect the muscles and bones. Dystrophin is a protein found in muscle cells that helps to maintain muscle structure and function. Deficiencies in dystrophin can lead to a range of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD). Treatments for DMD focus on replacing the missing dystrophin protein, either through gene therapy or protein replacement therapy. Several companies are involved in the Dystrophin market, including Sarepta Therapeutics, Pfizer, and Solid Biosciences. Sarepta Therapeutics is a biopharmaceutical company that develops treatments for rare neuromuscular diseases, including DMD. Pfizer is a global pharmaceutical company that has developed a gene therapy for DMD. Solid Biosciences is a biotechnology company that is developing a gene therapy for DMD. Show Less Read more